Genetic differences in follicular thyroid carcinoma between Asian and Western countries: a systematic review
- PMID: 33224857
- PMCID: PMC7667107
- DOI: 10.21037/gs-20-356
Genetic differences in follicular thyroid carcinoma between Asian and Western countries: a systematic review
Abstract
Thyroid cancer is the most common endocrine malignancy, and follicular thyroid carcinoma (FTC) is the second most common thyroid cancer following papillary thyroid carcinoma (PTC). RAS mutation and PAX8/PPARγ rearrangement are the two representative genetic alterations in FTC, and there are studies from various countries on their regional frequencies. In this study, we systematically reviewed all available literature aiming to create a complete global map showing the frequencies of these common oncogenic drivers in FTC and to highlight the trends in Asian and Western countries. We performed a search in two electronic databases and identified 71 studies that fit our criteria from 1,329 studies found with our database search terms. There were 54 articles with 1,143 FTC patients and 39 articles with 764 FTC patients available for calculating the frequency of RAS mutation and PAX8/PPARγ rearrangement, respectively. NRAS mutation was the most frequent RAS mutation in all regions, followed by HRAS and KRAS mutation. The frequency of RAS mutation in Asian countries was higher than Western countries (34% vs. 27%, P=0.006) when the mutation detection method was not taken into account. In contrast, this difference in RAS mutation incidence between Asian and Western countries (28% vs. 25%, P=0.47) did not show up in our subgroup analysis incorporating only studies using direct sequencing method. The reported difference of RAS mutation frequency in the previous literature might not be due to the true prevalence of RAS mutation. They could be attributed to the difference in the detection method. As to PAX8/PPARγ rearrangement, Western countries overall had a much higher prevalence than Asian countries (23% vs. 4%, P<0.001), but some European countries had a low incidence, implying regional heterogeneity of PAX8/PPARγ rearrangement. A substantial lack of mutation data in FTC was found in several regions of the world such as Central Asia, Middle East, Africa, and Central and South America. Our results provide the most comprehensive global status of representative genetic alterations in FTC and highlight the similarities and differences between Asian and Western countries.
Keywords: Follicular thyroid carcinoma (FTC); PAX8/PPARγ; RAS; systematic review.
2020 Gland Surgery. All rights reserved.
Conflict of interest statement
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/gs-20-356). The series “Asian and Western Practice in Thyroid Pathology: Similarities and Differences” was commissioned by the editorial office without any funding or sponsorship. To reports grants from JSPS, during the conduct of the study. The authors have no other conflicts of interest to declare.
Figures
Similar articles
-
PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma.J Clin Endocrinol Metab. 2006 Jan;91(1):213-20. doi: 10.1210/jc.2005-1336. Epub 2005 Oct 11. J Clin Endocrinol Metab. 2006. PMID: 16219715
-
Clear Cell Change in Thyroid Carcinoma: A Clinicopathologic and Molecular Study with Identification of Variable Genetic Anomalies.Thyroid. 2017 Jun;27(6):819-824. doi: 10.1089/thy.2016.0631. Epub 2017 Apr 12. Thyroid. 2017. PMID: 28293986
-
Identification of a paired box gene 8-peroxisome proliferator-activated receptor gamma (PAX8-PPARgamma) rearrangement mosaicism in a patient with an autonomous functioning follicular thyroid carcinoma bearing an activating mutation in the TSH receptor.Endocr Relat Cancer. 2010 Jun 3;17(3):599-610. doi: 10.1677/ERC-09-0069. Print 2010 Sep. Endocr Relat Cancer. 2010. PMID: 20427420
-
[Pathogenesis of differentiated thyroid cancer (papillary and follicular)].Arq Bras Endocrinol Metabol. 2005 Oct;49(5):691-700. doi: 10.1590/s0004-27302005000500009. Epub 2006 Jan 23. Arq Bras Endocrinol Metabol. 2005. PMID: 16444351 Review. Portuguese.
-
Gene expression profile of human thyroid cancer in relation to its mutational status.J Mol Endocrinol. 2011 Nov 2;47(3):R91-103. doi: 10.1530/JME-11-0023. Print 2011 Dec. J Mol Endocrinol. 2011. PMID: 21798995 Review.
Cited by
-
Profile of BRAFV600E, BRAFK601E, NRAS, HRAS, and KRAS Mutational Status, and Clinicopathological Characteristics of Papillary Thyroid Carcinoma in Indonesian National Referral Hospital.Appl Clin Genet. 2023 May 25;16:99-110. doi: 10.2147/TACG.S412364. eCollection 2023. Appl Clin Genet. 2023. PMID: 37255533 Free PMC article.
-
Management of follicular thyroid carcinoma.Eur Thyroid J. 2024 Oct 16;13(5):e240146. doi: 10.1530/ETJ-24-0146. Print 2024 Oct 1. Eur Thyroid J. 2024. PMID: 39419099 Free PMC article. Review.
-
Developing Models to Predict BRAFV600E and RAS Mutational Status in Papillary Thyroid Carcinoma Using Clinicopathological Features and pERK1/2 Immunohistochemistry Expression.Biomedicines. 2023 Oct 16;11(10):2803. doi: 10.3390/biomedicines11102803. Biomedicines. 2023. PMID: 37893176 Free PMC article.
-
Progression of Follicular Thyroid Carcinomas to Anaplastic Thyroid Carcinomas: Molecular and Clinicopathologic Characteristics with Comparison to Papillary Thyroid Carcinoma-Derived Anaplastic Thyroid Carcinomas.Endocr Pathol. 2025 Sep 1;36(1):30. doi: 10.1007/s12022-025-09875-y. Endocr Pathol. 2025. PMID: 40887557
-
ZNF169 promotes thyroid cancer progression via upregulating FBXW10.Cell Div. 2025 Jan 28;20(1):3. doi: 10.1186/s13008-024-00139-5. Cell Div. 2025. PMID: 39875985 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous